HALO HALOZYME THERAPEUTICS, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1159036 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY45.0%
TTM net income YoY-18.5%
TTM EPS YoY-15.6%
Revenue 3-yr CAGR32.2%
Net income 3-yr CAGR24.1%
Margins
Gross margin82.3%
Operating margin37.4%
Net margin26.9%
FCF margin49.1%
EBITDA margin38.3%
Returns
ROE216.4%
ROA17.0%
ROIC (approx.)26.6%
Asset turnover0.63x
Leverage & solvency
Liabilities / assets101.6%
Debt / equity—
Current ratio3.88x
Interest coverage30.58x
Cash quality & payout
Operating cash flow / net income1.85x
Accruals ratio-14.5%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $492.97M | $481.00M | $376.71M | $451.77M | $354.26M | $325.72M | $264.86M | $298.01M |
| Cost of revenue | $82.47M | $79.17M | $79.24M | $78.77M | $55.24M | $46.36M | $48.40M | $42.05M |
| Gross profit | $410.50M | $401.83M | $297.47M | $373.00M | $299.02M | $279.36M | $216.46M | $255.95M |
| R&D expense | $27.78M | $27.66M | $25.56M | $31.90M | $17.25M | $17.54M | $14.80M | $20.44M |
| SG&A expense | $58.24M | $57.00M | $57.88M | $77.03M | $46.09M | $41.61M | $42.36M | $42.25M |
| Operating income | $294.97M | $287.65M | $184.52M | -$92.89M | $217.92M | $202.44M | $141.53M | $175.50M |
| Interest expense | $6.04M | $5.59M | $5.51M | $4.91M | $4.30M | $4.39M | $4.53M | $4.54M |
| Pretax income | $290.63M | $284.90M | $180.33M | -$100.85M | $218.96M | $204.94M | $143.83M | $178.21M |
| Income tax | $43.58M | $54.99M | $30.28M | $40.74M | $43.73M | $39.78M | $25.73M | $41.20M |
| Net income | $247.05M | $229.91M | $150.05M | -$141.59M | $175.22M | $165.16M | $118.09M | $137.01M |
| EBITDA | $299.67M | $292.15M | $188.74M | -$89.59M | $220.62M | $205.14M | $144.22M | $178.15M |
| EPS (basic) | 2.17 | 1.96 | 1.27 | — | 1.49 | 1.36 | 0.96 | — |
| EPS (diluted) | 2.01 | 1.90 | 1.22 | — | 1.43 | 1.33 | 0.93 | — |
| Weighted avg. shares (diluted) | 122.61M | 121.22M | 122.88M | — | 122.33M | 124.16M | 126.64M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.03B | $163.14M | $309.75M | $133.82M | $419.67M | $61.86M | $176.33M | $115.85M |
| Receivables | $518.59M | $453.33M | $457.99M | $426.27M | $343.54M | $315.07M | $304.02M | $288.20M |
| Inventory | $132.61M | $137.13M | $155.47M | $176.47M | $185.80M | $181.50M | $164.87M | $141.86M |
| Current assets | $1.85B | $933.02M | $1.00B | $825.21M | $1.33B | $1.12B | $1.26B | $1.09B |
| PP&E, net | $51.20M | $49.76M | $46.93M | $44.44M | $40.58M | $39.60M | $40.22M | $40.86M |
| Goodwill | $581.73M | $581.73M | $582.32M | $580.36M | $416.82M | $416.82M | $416.82M | $416.82M |
| Intangibles | $892.93M | $922.44M | $951.96M | $981.47M | $348.54M | $366.31M | $384.07M | $401.83M |
| Total assets | $3.47B | $2.58B | $2.67B | $2.53B | $2.22B | $2.05B | $2.20B | $2.06B |
| Current liabilities | $476.09M | $344.44M | $363.21M | $177.09M | $837.23M | $134.28M | $150.38M | $139.10M |
| Short-term debt | $305.61M | $208.97M | $208.74M | $0 | $710.68M | — | — | $0 |
| Long-term debt | $2.94B | $1.94B | $1.94B | $2.14B | $800.07M | $1.51B | $1.51B | $1.51B |
| Total debt | $3.25B | $2.15B | $2.14B | $2.14B | $1.51B | $1.51B | $1.51B | $1.51B |
| Total liabilities | $3.53B | $2.43B | $2.45B | $2.48B | $1.72B | $1.72B | $1.71B | $1.70B |
| Shareholders' equity | -$55.24M | $143.54M | $219.64M | $48.81M | $503.92M | $332.75M | $482.27M | $363.82M |
| Net debt | $2.22B | $1.98B | $1.83B | $2.01B | $1.09B | $1.45B | $1.33B | $1.39B |
| Shares outstanding | 113.94M | 114.04M | 118.52M | 117.78M | 117.52M | 117.62M | 123.17M | 123.14M |
| Cash flow statement | ||||||||
| Operating cash flow | $258.27M | $240.89M | $180.08M | $219.03M | $178.60M | $99.71M | $154.22M | $178.47M |
| Capital expenditure | $3.05M | $4.17M | $3.74M | $1.43M | $3.03M | $1.56M | $950,000 | $3.05M |
| Free cash flow | $255.22M | $236.72M | $176.34M | $217.60M | $175.57M | $98.15M | $153.27M | $175.41M |
| Investing cash flow | $20.95M | -$62.66M | -$2.88M | -$741.79M | $201.61M | $84.79M | -$90.42M | $29.48M |
| Financing cash flow | $587.64M | -$326.25M | -$1.61M | $239.51M | -$22.40M | -$298.97M | -$3.32M | -$246.41M |
| Depreciation & amortization | $4.70M | $4.50M | $4.22M | $3.30M | $2.70M | $2.70M | $2.69M | $2.65M |
| Stock-based compensation | $16.80M | $17.70M | $16.64M | $16.57M | $12.16M | $12.16M | $10.67M | $11.46M |
| Share buybacks | $67.27M | — | — | $0 | $38.88M | — | — | $250.00M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.